Reference number	
1745-H	

SPECIALTY QUANTITY LIMIT PROGRAM

KINERET (anakinra)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit	FDA-recommended dosing
Kineret (anakinra) injection 100 mg/0.67 mL single-use prefilled syringe	240 syringes per 30 days	360 syringes per 30 days*	Rheumatoid arthritis: 100 mg per day Cryopyrin-Associated Periodic Syndromes (CAPS)/Neonatal- Onset Multisystem Inflammatory Disease (NOMID): up to 8 mg/kg per day

^{*} Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Kineret [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); June 2018.

Specialty Quantity Limit Kineret 1745-H P2019

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of